Supplementary Figure S9: Treatment of MiaPaCa2-xenografts with the SGS6 therapy. Subcutaneous, bilateral MiaPaCa2
tumors of NMRI nu/nu mice were treated every second day with 10 μg of in vivo jet-PEI complexed SGS6 siRNA for 16 d (4-6 tumors per group). (A) Tumor volumes were measured during therapy and (B) their weight was analyzed after preparation at day 18. Means ± standard errors are shown and an unpaired Student's t-test was used to compare the differences between the negative control (NC) and the SGS6 treated tumors (*p ≤ 0,05). 
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G12V WT primary tumor pleural effusion primary tumor lymph node metastasis primary tumor primary tumor liver metastasis ascites As negative control we used Allstars siRNA (Qiagen, Hilden, Germany), as positive control siRNA targeting KIF11/Eg5, an essential cytoskeletal component. 

